Tuesday, September 24, 2019

Venue and Hospitality

Welcome to the Official Attendee Housing Site for the 16th World Congress on Vascular Dementia and Neurodegenerative disorders, scheduled at Osaka,Japan. Accommodations will be provided at
Conference Venue:-
Hyatt Regency
Osaka 1-13-11 Nanko-Kita, Suminoe-Ku
Osaka, Japan, 559-0034
Conference DatesMay 18-19, 2020
Attractions & Landmarks



Osaka, Castle

The castle tower is surrounded by secondary citadels, gates, turrets, impressive stone walls and moats. The Nishinomaru Garden, encompassing the former "western citadel", is a lawn garden with 600 cherry trees, a tea house, the former Osaka Guest House and nice views of the castle tower from below. Unlike most of the rest of the castle grounds, the garden requires an admission fee.
The entire Osaka Castle Park covers about two square kilometers with lots of green space, sport facilities, a multi-purpose arena (Osakajo Hall) and a shrine dedicated to Toyotomi Hideyoshi. The park is one of Osaka's most popular hanami spots during the cherry blossom season, which usually takes place in early April.
Dotonbori.
The lively entertainment area of Dotonbori is Osaka’s most famous tourist destination and renowned for its gaudy neon lights, extravagant signage, and the enormous variety of restaurants and bars.
The name “Dotonbori” generally refers both to the Dotonbori Canal and to Dotonbori Street which runs parallel to the canal’s southern bank. It is one of the most colorful areas in Osaka and an absolute must-visit location when traveling through Kansai region.
Shinsaibashi


Shinsaibashi-Suji Shopping Street, which runs east to Mido-Suji Avenue, is the best-known shopping area in Osaka, and an enduring symbol of the city. With a history of 380 years, it was already an established shopping area in the Edo Period. Shops of all kinds and for all ages line the street, a roofed arcade 600 meters long. There are traditional kimono tailors, western clothing and footwear retailers, restaurants and fast food outlets, jewelers, and boutiques featuring the latest fashions. It?'s great to take a casual stroll through the Shinsaibashi area. Many people enjoy window-shopping and savoring the food along the way.
Kuromon Ichiba is a lively covered market which stretches for 580 meters in Osaka’s Chuo Ward. Nicknamed “Osaka’s kitchen” because both local homeowners and restaurant chefs get their supplies here, the market is famous for its fresh seafood and has recently become a popular tourist location. As a result it can get quite crowded. In 2015 the market was visited by an average of 23,000 people a day, but that figure is most probably higher now. One reason for the market’s popularity is that many stalls will prepare, cook and serve their food to you right on the spot. 
Osaka’s Universal Studios Japan (USJ) is a must-see attraction for many visitors to Japan. Here is our full guide, with transport information, ticket information and insider tips to skipping lines and getting the most out of your visit.
Universal Studios Japan (USJ) is a popular theme park in Osaka City. USJ attracts visitors from all around the world, and it’s one of the most visited amusement that invited approx 15 million people a year. Along with the fun and thrilling attraction rides and shows, the character merchandise collections at Universal Studios Japan are hugely popular among visitors worldwide. Minions, Sesame Street, Snoopy, Hello Kitty.. popular and adorable character themed products are perfect for souvenir gifts, and they are available at souvenir stores at the park. Besides the regular merchandise collections, the seasonal limited collections are also very popular such as Halloween, Christmas and more.




Wednesday, September 4, 2019

Market Analysis

16th World Congress on Vascular Dementia and Neurodegenerative Diseases is a yearly meeting of Neuroscience organizations as well as Dementia committees to debate the future of the vascular dementia in terms of collaboration, structures and executive development. Brain investigators, public health specialists, scientists, academic experts, Industry intellectuals, scholars to exchange about state of the art research and technologies. Intention of this conference is to inspire new ideas for treatment that will be favourable across the spectrum of Vascular Dementia Congress 2020. Conferences, National symposiums and Workshops provide a dedicated opportunity for the advancement, implementation and exchange of information about Vascular Dementia Congress 2020 and its associated areas.

Why Osaka?

Dementia predominantly occurs in older people and, in view of the current demographic trend, has become a major issue for society and health policy.  Currently around 130,000 people in Austria are suffering from some form of dementia and experts estimate that this number will double by 2050. Accounting for around 60 – 80% of cases, Alzheimer's disease is by far the most common form of dementia.

Osaka is the second biggest Metropolitan range in Japan. Glorify in the large number of individuals encountering mental issues excuse the perseverance of 40 affiliations and social orders subsidiary to Neuroscience in Osaka and Japan. Japan is dislodging towards contemporary brain research industry from its conventional "shinrigaku".

Otherwise called the "Country's Kitchen", Osaka is a noteworthy financial center point, facilitating almost 19 million individuals. The GDP in Osaka is about $341 Billion. Alongside Paris and London, it is a standout amongst the most gainful hinterlands on the planet. Osaka is the second most costly city for ostracize workers on the planet 2009.

Osaka is known for its cutting edge design, nightlife and healthy road nourishment. The sixteenth Century Osaka Castle is the real fascination in this city alongside the clamoring Umeda Underground Mall and Namba Park.

Osaka, in Japan is an international hub for transport and health care, and has emerged as a regional centre for the arts, fashion and entertainment. The city is well known for its vibrant street life and cultural landmarks. Osaka is rapidly growing amidst little urban planning and regulation has resulted in a haphazard cityscape and inadequate infrastructure systems.  The city grew rapidly during the 1960s through the 1980s and now exerts a significant impact on Japan's politics, economy, education, media and modern society.

Conference Highlights:

•           Dementia

•           Dementia stages

•           Vascular Dementia

•           Causes of Vascular Dementia

•           Symptoms of Vascular Dementia

•           Lewy Body Dementia

•           Diagnosis

•           Dementia Nursing

•           Dementia care management

•           Treatment

•           Animal models

•           Neurodegenerative diseases

•           Neurooncology and CNS

•           Neuropharmacology

•           Vascular cognitive impairment

•           Therapeutic targets

•           Clinical trials and drug development

•           Neuroimmunology

•           Neuroradiology

•           Neurotoxicity of drug abuse

Why to attend?

16th World Congress on Vascular Dementia and Neurodegenerative Diseases is a single forum to bring together worldwide eminent academics in the field of neuroscience and neurology, Brain investigators, public health experts, scientists, academic geniuses, industry researchers, scholars to exchange about state of the art research and skills.

Meet Your Target Market With members from around the world focused on learning about the latest innovations in screening and treatments for Vascular Dementia and Neurodegenerative diseases; this is your single best opportunity to reach the largest assemblage of participants from the Universities, Neurology research centers and hospitals and conduct demonstrations of new screening instruments, distribute information about novel agents and strategies, meet with highly affiliated speakers, showing of clinical trials as well as advancements in new Dementia and neurodegenerative therapies, current methods and controversies in psychic therapy and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques for screening as well as for treatment, and the newest updates in Vascular Dementia and Neurodegenerative disorders and treatments are hallmarks of this conference.

According to WHO 47.5 million people have dementia and every year 7.7 million new cases are appearing. By 2030 total cases of dementia is projected to be 75.6 million and almost triple by 2050 to 135.5 million. Alzheimer’s disease contributes 60-70 % of cases in dementia and second most common condition of dementia is vascular dementia which contributes 20% of cases all over the world. Total estimated cost of dementia is 818 billion US $ in 2015.

With members from around the world focused on learning about various Alzheimer’s disease and how to prevent the disorders. This is your best opportunity to reach the largest assemblage of participants from the entire world.

At the Dementia conferences and from the eminent people speech, you can update your knowledge about current situation of Dementia  research and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Dementia fields are hallmarks of this conference.

Intention of this conference is inspire new ideas for treatment that will be helpful across the spectrum of Vascular Dementia Congress 2020

Importance and scope

From every corner of the world, someone develops dementia every 3 seconds. This was an estimated value at 46.8 million people worldwide living with dementia in 2015 and the number is expected to be close to 50 million people in 2017. This number may double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Mostly it is observed too be increased in developing countries. For now, 58% of people with dementia are living in low and middle income countries, may be, by 2050 this can rise to 68%.

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered with vascular dementia during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 per cent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated in increase to 63 per cent in 2030 and 71 per cent in 2050.The values are expected to double by 2030 and triple by 2050 to 115 million.

Glance at market of dementia:-

The total estimated worldwide cost of dementia is US$818 billion in 2015, which represents 1.09% of global GDP. By 2018, the global cost of dementia will rise above a US$ trillion.

This figure includes costs attributed to informal care (unpaid care provided by family and others), direct costs of social care (provided by community care professionals, and in residential home settings) and the direct costs of medical care (the costs of treating dementia and other conditions in primary and secondary care).

Direct medical care costs account for roughly 20% of global dementia costs, while direct social sector costs and informal care costs each account for roughly 40%. The relative contribution of informal care is greatest in the African regions and lowest in North America, Western Europe and some South American regions, while the reverse is true for social sector costs.

This means that if global dementia care were a country, it would be the 18th largest economy in the world. The annual costs exceed the market values of companies such as Apple (US $742 billion) and Google (US $368 billion). More information is available in our World Alzheimer Report 2015.suffer from Alzheimer’s disease.

Top Universities globally working in the field of vascular Dementia.

•         Harvard University

•         University College London

•         University of California--San Francisco

•         Stanford University

•         Massachusetts Institute of Technology

•         Johns Hopkins University

•         University of California--Los Angeles

•         University of California--San Diego

•         Columbia University

•         University of Oxford

•         Karolinska Institute

Top Hospitals Associated with Vascular Dementia Research in World.

•         John Hopkins Medicine

•         Massachusetts General Hospital

•         Siloam Hospitals

•         Mayo Clinic

•         The Mount Sinai Hospital

•         Jefferson Hospital for Neuroscience

•         Neurology Florida Hospital

•         UNM Neurology Centre

•         Tampa General Hospital

•         Huntington Hospital

•         EI Camino Hospital

There are above Companies Associated with Vascular Dementia Research in World.

•         Forest Laboratories

•         Janssen Pharmaceuticals

•         Novartis Pharmaceutical Corporation

•         Pfizer

•         Eisai

•         Actinogen Limited

•         Alector LLC

•         AlzProtect SAS

•         TauRx Therapeutics Ltd

Tuesday, August 27, 2019

Session/ Tracks of Vascular Dementia Congress 2020


Session 1: Dementia

Dementia is a chronic or persistent disorder of the mental ability process caused by brain diseases or injuries marked due to personality changes, memory disorders and impaired reasoning. Dementia is not a specific disease. It's a group of symptoms related with a decline in memory or other thinking ability skills enough to reduce a person's ability activities. Various kinds of dementia are associated with particular types of brain cell damage in particular regions of the brain.

Dementia is often incorrectly referred to as "senility" or "senile dementia," which reflects the formerly widespread but incorrect belief that serious mental decline is a normal part of aging.

Dementia is a syndrome – usually of a chronic or progressive nature – in which there is deterioration in cognitive function (i.e. the ability to process thought) beyond what might be expected from normal aging. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. Consciousness is not affected. The impairment in cognitive function is commonly accompanied, and occasionally preceded, by deterioration in emotional control, social behaviour, or motivation.

Session 2: Dementia stages

Dementia in stages refers how far a person’s dementia has been progressed. It defines a person’s disease stage helping physicians to determine the best treatment approach and aid communication between health providers and caregivers. Sometimes the stage is simply referred to as “Early stage”, “Middle stage” or “Late-stage” dementia, but often a more exact stage is assigned, based on a person’s symptoms.

Early stage: the early stage of dementia is often overlooked, because the onset is gradual.

Middle stage: as dementia progresses to the middle stage, the signs and symptoms become clearer and more restricting.

Late stage: the late stage of dementia is one of near total dependence and inactivity. Memory disturbances are serious and the physical signs and symptoms become more obvious.

A more exact stage is assigned, based on a person’s symptoms.

•           Global Deterioration Scale for Assessment of Primary Degenerative Dementia (GDS)

•           Cognitive Decline

•           Very Mild Cognitive Decline

•           Mild Cognitive Decline

•           Moderate Cognitive Decline

•           Moderately Severe Cognitive Decline

•           Severe Cognitive Decline (Middle Dementia)

•           Very Severe Cognitive Decline (Late Dementia)

•           Functional Assessment Staging (FAST)

•           Clinical Dementia Rating (CDR) – No dementia, Moderate, Mild, Severe.


Session 3: Vascular Dementia

Vascular dementia, also known as multi-infarct dementia, is the second most common dementia type in older people. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. It happens when part of the brain doesn't get enough blood carrying the oxygen and nutrients it needs. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Thinking problems also may begin as mild changes that worsen gradually as a result of multiple minor strokes or other conditions that affect smaller blood vessels, leading to cumulative damage.

Vascular dementia symptoms can vary widely, depending on the severity of the blood vessel damage and the part of the brain affected. Memory loss may or may not be a significant symptom depending on the specific brain areas where blood flow is reduced. Symptoms may be most obvious when they happen soon after a major stroke

Factors that increase your risk of heart disease and stroke — including diabetes, high blood pressure, high cholesterol and smoking — also raise your vascular dementia risk. Controlling these factors may help lower your chances of developing vascular dementia.


Session 4: Causes of vascular dementia

Vascular dementia occurs when vessels that supply blood to the brain become blocked or narrowed. Strokes take place when the supply of blood carrying oxygen to the brain is suddenly cut off. However, not all people with stroke will develop vascular dementia.

Vascular dementia can occur over time as "silent" strokes pile up. Quite often, vascular dementia draws attention to itself only when the impact of so many strokes adds up to significant disability. Avoiding and controlling risk factors such as diabetes, high blood pressure, smoking, and high cholesterol can help curb the risk of vascular dementia.


Session 5: Symptoms of vascular dementia

Symptoms of vascular dementia depend on what part of the brain is affected and to what extent. Like Alzheimer's disease, the symptoms of vascular dementia are often mild for a long time. They may include:

•           Problems with short-term memory

•           Wandering or getting lost in familiar surroundings

•           Laughing or crying at inappropriate times

•           Trouble concentrating, planning, or following through on activities

•           Trouble managing money

•           Inability to follow instructions

•           Loss of bladder or bowel control

•           Hallucinations or delusions

Symptoms that suddenly get worse often signal a stroke. Doctors look for symptoms that progress in noticeable stages to diagnose vascular dementia. Alzheimer's, by comparison, progresses at a slow, steady pace. Another clue is impaired coordination or balance. In vascular dementia, problems walking or balancing can happen early. With Alzheimer's, these symptoms usually occur late in the disease.

Session 6: Lewy body Dementia

Lewy body is also known as dementia with Lewy bodies, with Lewy body dementia is the second most common type of progressive dementia after Alzheimer's disease dementia. Protein deposits, called Lewy bodies, develop in nerve cells in the brain regions involved in thinking, memory and movement (motor control). People with Lewy body dementia have a progressive decline in their memory and ability to think; similar to Alzheimer’s disease. However, the cognitive ability or alertness of a person with Lewy body dementia is more likely to fluctuate from one moment to the next, which is not like Alzheimer’s disease. They also often have visual hallucinations (seeing things that aren’t there) and delusions (believing something that is not true). On the surface, people with Lewy body dementia often have problems with movement that resemble Parkinson’s disease. This is because the same structures of the brain are affected in Lewy body dementia and Parkinson’s disease.

•           Causes of Lewy Body Dementia

•           Symptoms of Lewy Body Dementia

•           Diagnosing Lewy Body

•           Dementia Cholinesterase Inhibitors

•           Diagnosing dementia (general)

•           Treating dementia

Session 7: Diagnosis of Vascular dementia

There's no specific test that confirms you have vascular dementia. Diagnosis of vascular dementia is done by medical history for stroke or disorders of the heart and blood vessels, and results of tests that may help clarify your diagnosis.

•Lab tests

Lab diagnosis of vascular dementia is done by testing blood pressure, cholesterol, blood sugar or by testing thyroid disorders and vitamin deficiencies

•Brain imaging

Images of your brain can pinpoint visible abnormalities caused by strokes, blood vessel diseases, tumors or trauma that may cause changes in thinking and reasoning.

•Computerized tomography (CT) scan

A CT scan can provide information about your brain's structure; tell whether any regions show shrinkage; and detect evidence of strokes, ministrokes (transient ischemic attacks), blood vessel changes or tumors.

•Magnetic resonance imaging (MRI).

An MRI uses radio waves and a strong magnetic field to produce detailed images of your brain. MRIs are generally the preferred imaging test because MRI can provide even more detail than CT scans about strokes, ministrokes and blood vessel abnormalities.

•Carotid ultrasound

This procedure uses high-frequency sound waves to determine whether your carotid arteries which run up through either side of your neck to supply blood to the brain which shows signs of narrowing as a result of plaque deposits or structural problems. This test may include a Doppler ultrasound, which shows the movement of blood through arteries in addition to structural features.

•Amyloid Imaging in Dementia

Amyloid imaging is a technique performed in nuclear medicine. It uses PET ligands that allow in vivo detection of amyloid plaques, a core pathologic feature of Alzheimer disease and dementia.

Session 8: Dementia Nursing

Caregivers of dementia patients need to understand dementia so that they can understand what the patient is going through. They need to know about underlying diseases, and how these may affect the progress of dementia. They also need to know what sort of behavior to expect. Understanding these helps them plan for their caregiving and to cope with the situation effectively, and with less stress.

People with Dementia and vascular dementia have different mental element shortfalls that incorporate every memory hindrance, that influences the adaptability to discover new data or review data already learned, and one or extra of the ensuing side effects aphasia, apraxia, agnosia, or official brokenness to such an extent that the mental element shortages adversely affect social or action working with a major decrease in past abilities. Furthermore, people with dementia commonly experience the ill effects of comorbid conditions that extra confuse mind and block best results. Along these lines, creating caregiving techniques individuals with vascular dementia is pressing, given this expanding commonness and consequently the related weight that dementia places not just on the people, however on the parental figures, relations, and thusly the assets of the human services framework. Traditional perspectives bearing on geriatric nursing ordinarily paint a picture of the care as being moderate paced certain and less requesting than intense care. Be that as it may, care of the matured, and especially those with vascular dementia, is normally confounded, unusual, and flimsy.

•           Dementia nursing care plan

•           Music therapy in dementia

•           Physiotherapy for dementia

•           Clinical features of dementia

•           Therapeutic interventions in dementia

Session 9: Dementia Care Management

Treatment of dementia depends on its cause. In the case of most progressive dementias, including Alzheimer's disease, there is no cure and no treatment that slows or stops its progression. But there are drug treatments that may temporarily improve symptoms. The same medications used to treat Alzheimer's are among the drugs sometimes prescribed to help with symptoms of other types of dementias. Non-drug therapies can also alleviate some symptoms of dementia.

•           Psychopharmacological treatment

•           Psychopharmacological treatment

•           Advanced drugs for dementia

•           Cognitive behavioral therapy

•           Family therapy in nursing

Session 10: Treatment of Dementia

Treatment of dementia begins with the treatment of the underlying disease, where possible. The underlying causes of nutritional, hormonal, tumour-caused or drug-related dementia may be reversible to some extent. For many other diseases, such as Alzheimer's disease (AD), no cure has yet been discovered. However, improvement of cognitive and behavioural symptoms can be achieved through a combination of appropriate medications and other treatments, including psychotherapy.

There are also a number of therapies and practical measures that can help make everyday living easier for someone with dementia.

These include:

•occupational therapy to identify problem areas in everyday life, such as getting dressed, and help with working out practical solutions

•speech and language therapy to help improve any communication problems

•physiotherapy to help with movement difficulties

•psychological therapies, such as cognitive stimulation (activities and exercises designed to improve memory, problem-solving skills and language ability)

•relaxation techniques, such as massage and music or dance therapy

•social interaction, leisure activities and other dementia activities, such as memory cafes (drop-in sessions for people with memory problems and their carers to get support and advice)

•home modifications, such as removing loose carpets and potential trip hazards, ensuring the home is well lit, and adding grab bars and handrails

Session 11: Animal Models in Dementia

Dementia is a clinical syndrome with abnormal degree of memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease. Recent advances in the understanding of the pathophysiological mechanisms underlying Alzheimer's disease and other cognitive deficits have pointed to novel strategies for drug development. Animal models have contributed noticeably to these advances and are an indispensible part in the evaluation of therapeutics.

The critical evaluations of current rodent models of dementia and discussion about their role in drug discovery and development have been carried out. Since dementia has multiple pathophysiological mechanisms, we have tried to provide a detailed description of various types of animal models which would depict different pathophysiological stages and causes of dementia. This review aims to better understand the prognosis, biochemical, and behavioral alterations that occur during dementia and hence facilitate drug discovery and development.

Session12: Neurodegenerative Diseases

Neurodegenerative disease primarily affects the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias). Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.

•           Alzheimer’s disease (AD) and other dementias

•           Parkinson’s disease (PD) and PD-related disorders

•           Prion disease

•           Motor neurone diseases (MND)

•           Huntington’s disease (HD)

•           Spinocerebellar ataxia (SCA)

•           Spinal muscular atrophy (SMA)

Session 13: Neuro Oncology and CNS

It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects.

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (highly anaplastic) astrocytoma are among the worst.

The CNS consists of the brain and spinal cord. The brain is protected by the skull (the cranial cavity) and the spinal cord travels from the back of the brain, down the center of the spine, stopping in the lumbar region of the lower back. The brain and spinal cord are both housed within a protective triple-layered membrane called the meninges.

•           Brain Stem Tumors

•           Spine Diseases

•           Glioblastoma

•           Meningioma

•           Malignant Brain Cancers and Brain Metastasis

•           Pediatric Neuro Oncology

•           Astrocytoma

•           Neurotoxicity

Session 14: Neuropharmacology

Neuropharmacology is the scientific study of the effects of drugs on the nervous system. Its primary focus is the actions of medications for psychiatric and neurologic disorders as well as those of drugs of abuse. Drugs that act on the nervous system, including antidepressant, antianxiety, anticonvulsant, and antipsychotic agents, are among the most widely prescribed medications.

Neuropharmacology is the study of the effects of drugs on the nervous system, with the goal of developing compounds that offer therapeutic benefit in humans with psychiatric and neurological disease. We believe that an understanding of a drug’s action requires an integrated knowledge of the cellular and molecular mechanisms by which the drug exerts its effects upon brain circuitry and ultimately human behaviour.

Consequently, the research conducted within the department encompasses many aspects of modern molecular and cellular neuroscience taking full advantage of modern research techniques such as opto-genetics, high-resolution cellular imaging, STEM cell biology and electrophysiology.

Session 15: Vascular Cognitive Impairment

Vascular cognitive impairment is a decline in thinking abilities caused by disease that damages the brain’s blood vessels. Vascular disease may cause cognitive impairment on its own, and can also contribute to impairments in thinking and behaviour in a person with another brain disease such as Alzheimer’s.

Vascular cognitive impairment refers to all forms of cognitive disorder associated with cerebrovascular disease, regardless of the specific mechanisms involved. It encompasses the full range of cognitive deficits from mild cognitive impairment to dementia. In principle, any of the multiple causes of clinical stroke can cause vascular cognitive impairment.

Vascular brain injury results in loss of structural and functional connectivity and, hence, compromise of functional networks within the brain. Vascular cognitive impairment is common both after stroke and in stroke-free individuals presenting to dementia clinics, and vascular pathology frequently coexists with neurodegenerative pathology, resulting in mixed forms of mild cognitive impairment or dementia.

Session 16: Therapeutic Targets

Therapeutic targets are bio molecules maybe a nucleic acid or a protein whose biological activity can be modified by a drug candidate. In some cases of Dementia, it is reported that proteins are the cause for the disease. For example the accumulation of amyloid protein in the regions of Brain acts as a major factor for the disorder; hence it can be a therapeutic target. Therapeutic targets play an important role in identifying the potential drug candidates. Hence the conference provides the discussion sessions to reveal the targets for drug design process.

•           Beta-amyloid Precursor Protein

•           Action of Protein tau

•           Role of Acetylcholinesterase and Inhibition

•           N-methyl-d-aspartate (NMDA) receptor as target

•           Processing of Prion Protein

Session 17: Clinical Trials and Drug Development

Rigorous clinical trials on Dementia drugs are continuing in USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. The most of drugs are in second and third phases. Most of clinical trials are done in specific areas are amyloid beta plaques, the immune system, tau tangles. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. There are many developments are going on in Drug discovery of Dementia as old treatments are unable to stop the progression of Dementia. Most associations share their exploration on new medications for Dementia in Dementia conferences to get higher esteem to their items. This gets to be distinctly gainful to different geriatric doctors to redesign themselves with such medications and progressing possibilities by going to Dementia conferences. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offers positivity to discover new approaches in curing Dementia

•           Development of Re-purposed Drugs

•           Beta-amyloid Polymerization and Inflammation Inhibitor

•           Prevention Trials

•           Anticonvulsant Drugs for Treatment

•           Vaccine Development against Beta-Amyloid

•           Animal Models for Toxicology Studies


Session 18:   Neuroimmunology

The Immunotherapy treats the Immune system in Injury and repair during wide range of Neurological disorders, Inflammatory and Autoimmune Diseases of the Nervous system such as Multiple Sclerosis (MS) and Neuromyelitis Optical (NMO) and several Brain Tumor conditions. There were numerous Radiological studies to improve Diagnosis and treatment of these diseases. The main focus is to develop the so-called Neuroprotective (nerve cell protecting) treatment approaching and establishing Modern examination procedures such as MRI (Magnetic Resonance Imaging), OCT (Optical Coherence Tomography) and Motion Analysis.

Related Conferences: Neurology and Psychiatric Meetings | Mental health and Neuroscience summit | Psychology and Neurological disorders conferences | 28th World Congress on Neurology and Therapeutics | 7th Global Annual Meeting on Neurology and NeuroSurgery | 2nd International Conference on Epilepsy and Treatment

Related Associations: Cyprus Neurological Society | Czech Society of Neurology | Danish Neurological Society | Estonian Society of Neurologists & Neurosurgeons | Finnish Neurological Association | American Association of Neurological Surgeons (AANS) | Georgian Society of Neurologists

Session 19:  Neuroradiology

Neuroradiology uses primary imaging modalities including computed tomography (CT) and magnetic resonance imaging (MRI) to focus on Endovascular or minimally invasive diagnosis and characterization of abnormalities of the Central Nervous System or head and neck lesions such as Tumors, Aneurysms, Vascular malformations, or Stroke. It involves different types of Imaging Studies like Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) for characterization of various Neurological disorders.

Session 20: Neurotoxicity of Drug Abuse

Neurotoxicity is considered as a major cause of neurodegenerative disorders. Most drugs of abuse have non-negligible neurotoxic impacts a significant number of which are essentially interceded by a few dopaminergic and glutamatergic neurotransmitter frameworks. Neurotoxicity and formative neurotoxicities are imperative antagonistic wellbeing impacts of several ecological contaminants and word related synthetic substances, regular poisons and pharmaceutical medications.


Session 21:  Alzheimer’s disease

Alzheimer’s is a neurological cerebrum issue. This Alzheimer’s sickness is the most widely recognized type if dementia, the gathering of scatters that will disable the mind working. Memory loss is the most punctual indications for this disease, reduces the thinking capacities and changes in identity or contact. Thus, Vascular Dementia 2019 may give helpful focuses to the Alzheimer’s sickness and detail part of neurological science.

Session 22: Aging and Dementia

Age-related memory impairment and dementia can be stated apart in several ways. Also, in adults younger than 60 will be affected rare with dementia, but dementia becomes increasingly common after 60 ages. Understanding the back-and-forth between psychology and brain changes is a vital step in the direction of improving how we age and auxiliary to healthy ageing in society. The Vascular Dementia 2019 aims to describe how our inward lives changes as we age, both as healthy and disease.

Session 23: Advances in Dementia Diagnosis

A diagnosis of dementia entails that at least two core mental purposes be lessened enough to affect with daily existing. Cognitive and Neuropsychological tests can be used to measure thinking skills. The memory treatment has been designated great significances for patients with dementia. The neurological evaluation is the treatment for problem-solving, visual perception and movement. Brain scans are like CT or MRI and PET scans are shows the patters of the brain activity if the amyloid protein had been deposited in the brain. The Conference on Vascular Dementia 2019 has taken one segment closer to dementia therapy.


Session 24: Potential Future Interventions

According to the research, the estimated the burden of late-onset dementia in the UK over 2025 and weigh the impact of potential interventions. The compute infirmity adjusted life years over 2025 and consider 3 interventions, all assumes launched in 2018; an expectant restrictive case of a 100% preventive intervention with instant uptake of 100% of the population at risk; an intervention which delays onset by 5 years, linear uptake to 50% after 5 years; but uptake 75% after 5 years.

By 2025, the disability-adjusted life years burden will have increased by 42% from the Global Disease Burden 2010 as estimated. Intervention results: some 9% decreases by 2025; a 33% increases; and a 28% increases.

Session 25: Recent Studies & Case Reports

Dementia may be a progressive, irreversible decline in intelligence that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementedness has many etiologies of that Alzheimer’s sickness is that the most typical.

Drug development in Alzheimer’s sickness is predicated on evolving pathophysiological theory. Sickness modifying approaches embrace the targeting of amyloid process, aggregation of alphabetic character, endocrine signal, neuro-inflammation and neurochemical pathology, with efforts to date yielding abandoned hopes and current promise. Reflective its dominance on the pathophysiological stage the amyloid cascade is central to several of the rising drug therapies.

Tuesday, August 20, 2019

About Conference

Conference Series is currently bringing “16th World Congress on Vascular Dementia and Neurodegenerative Diseases” (Vascular Dementia Congress 2020) programmed to be held during May 18-19, 2020 at Osaka, Japan. The conference invites all the participants across the globe to attend and share their visions and convey current developments in the field of Dementia and Neurodegenerative diseases.

The session will be organized around the theme ‘Share the vision on Vascular Dementia and Neurodegenerative diseases'. We will likely convey an extraordinary program which covers the complete range of research in Dementia issue and Neurodegenerative diseases and share the ethnically diverse meetings of different treatment methodology.

Vascular dementia Congress 2020 is a yearly meeting of Neuroscience organizations as well as Dementia committees to debate the future of the Vascular Dementia in terms of collaboration, structures and organizational development.

Target Audience:

Business ambassadors, Industrial Frontrunners, Stroke Scientists, Neuro Oncologists, CEO's and R&D Heads  from Industries, Directors, Neurologist, Neurosurgeons, Psychiatrist, Neuroscientist, Head of department, Professors and Students from Academia in the research of neurological disorders.

Exhibition:

Why exhibit?

Make sales

Debut new products

Profile your brand

Meet new business partners and suppliers

Develop key relationships

Educate healthcare, medical institutions and academia

Who you will meet?

Leaders in:

Neurology

Neurosurgery

Vascular Dementia

Dementia

Neurological Disorders

Neuro Degeneration

Cerebrovascular disorders

Spine & Spinal Disorders

Stroke

Brain Tumors & Neuro Oncology

Neuropsychiatry and Mental health

Neuropharmacology

Why to attend?

16th World Congress on Vascular Dementia and Neurodegenerative Diseases an unique of a kind gathering to unite global recognized scholastics in the field of neuroscience and neurology, Brain specialists, general wellbeing professionals, researchers, scholastic reviewers, industry specialists, researchers to trade about best in class investigation and modernizations.

Aim of this conference is inspire new ideas for treatment that will be beneficial across the spectrum of Vascular Dementia Congress 2020

Venue and Hospitality

Welcome to the Official Attendee Housing Site for the  16th World Congress on Vascular Dementia and Neurodegenerative disorders , schedule...